Introduction In the mid 1990s, immunoassays for C-reactive protein (CRP), with greater sensitivity than those previously in routine use, revealed that increased CRP values, even within the range previously considered normal, strongly predict future coronary events. These findings triggered widespread interest, especially, remarkably, in the US, where the clinical use of CRP measurement had been largely ignored for about 30 years. CRP production is part of the nonspecific acute-phase response to most forms of inflammation, infection, and tissue damage and was therefore considered not to provide clinically useful information. Indeed, CRP values can never be diagnostic on their own and can only be interpreted at the bedside, in full knowledge of all other clinical and pathological results. However, they can then contribute powerfully to management, just as universal recording of the patient’s temperature, an equally nonspecific parameter, is of great clinical utility. The present torrent of studies of CRP in cardiovascular disease and associated conditions is facilitated by the ready commercial availability of automated CRP assays and of CRP itself as a research reagent. However, unlike the earlier rejection in the US of CRP as an empirical test because of […]

Find the latest version:

http://jci.me/18921-pdf
Introduction
In the mid 1990s, immunoassays for C-reactive protein (CRP), with greater sensitivity than those previously in routine use, revealed that increased CRP values, even within the range previously considered normal, strongly predict future coronary events. These findings triggered widespread interest, especially, remarkably, in the US, where the clinical use of CRP measurement had been largely ignored for about 30 years. CRP production is part of the nonspecific acute-phase response to most forms of inflammation, infection, and tissue damage and was therefore considered not to provide clinically useful information. Indeed, CRP values can never be diagnostic on their own and can only be interpreted at the bedside, in full knowledge of all other clinical and pathological results. However, they can then contribute powerfully to management, just as universal recording of the patient’s temperature, an equally nonspecific parameter, is of great clinical utility.

The present torrent of studies of CRP in cardiovascular disease and associated conditions is facilitated by the ready commercial availability of automated CRP assays and of CRP itself as a research reagent. However, unlike the earlier rejection in the US of CRP as an empirical test because of its perceived lack of specificity, the current enthusiasm over CRP in cardiovascular disease is widely characterized by failure to recognize appropriately the nonspecific nature of the acute-phase response, and by lack of critical biological judgment. Quality control of the source, purity, and structural and functional integrity of the CRP, and the relevance of experimental design before ascribing pathophysiological functions, are also often ignored.

This article provides information about CRP as a protein and an acute-phase reactant, and a knowledge-based framework for interpretation and analysis of clinical observations of CRP in relation to cardiovascular and other diseases. We also review the properties of CRP, its possible role in pathogenesis of disease, and our own observations that identify it as a possible therapeutic target.

The acute-phase response
CRP, named for its capacity to precipitate the somatic C-polysaccharide of Streptococcus pneumoniae, was the first acute-phase protein to be described and is an exquisitely sensitive systemic marker of inflammation and tissue damage (1). The acute-phase response comprises the nonspecific physiological and biochemical responses of endothermic animals to most forms of tissue damage, infection, inflammation, and malignant neoplasia. In particular, the synthesis of a number of proteins is rapidly upregulated, principally in hepatocytes, under the control of cytokines originating at the site of pathology. Other acute-phase proteins include proteinase inhibitors and coagulation, complement, and transport proteins, but the only molecule that displays sensitivity, response speed, and dynamic range comparable to those of CRP is serum amyloid A protein (SAA) (Table 1) (1).

Circulating CRP concentration
In healthy young adult volunteer blood donors, the median concentration of CRP is 0.8 mg/l, the 90th centile is 3.0 mg/l, and the 99th centile is 10 mg/l (2), but, following an acute-phase stimulus, values may increase from less than 50 μg/l to more than 500 mg/l, that is, 10,000-fold. Plasma CRP is produced only by hepatocytes, predominantly under transcriptional control by the cytokine IL-6, although other sites of local CRP synthesis and possibly secretion have been suggested. De novo hepatic synthesis starts very rapidly after a single stimulus, serum concentrations rising above 5 mg/l by about 6 hours and peaking around 48 hours. The plasma half-life of CRP is about 19 hours and is constant under all conditions of health and disease, so that the sole determinant of circulating CRP concentration is the synthesis rate (3), which thus directly reflects the intensity of the pathological process(es) stimulating CRP production. When the stimulus for increased production completely ceases, the circulating CRP concentration falls rapidly, at

C-reactive protein: a critical update
Mark B. Pepys and Gideon M. Hirschfield

Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine, Royal Free and University College Medical School, London, United Kingdom

almost the rate of plasma CRP clearance. In unselected
general populations of ostensibly healthy subjects, the
median CRP value is slightly higher than among blood
donors and tends to increase with age, presumably
reflecting the increasing incidence of subclinical
pathologies (4). However, surprisingly in view of the
sensitivity, speed, and range of the CRP response, sub-
jects in the general population tend to have stable CRP
concentrations characteristic for each individual, apart
from occasional spikes presumably related to minor or
subclinical infections, inflammation, or trauma. There
is no significant seasonal variation in base-line CRP
concentration, and, remarkably, the self correlation
coefficient of measurements repeated years apart is
about 0.5, which is comparable to that of cholesterol.
Twin studies show a highly significant hereditable
component in base-line CRP values that is independ-
ent of age and BMI. Associations between CRP pro-
duction and genetic polymorphisms in IL-1 and IL-6
have been suggested, and a polymorphic GT repeat in
the intron of the CRP gene is reportedly associated with
differences in base-line CRP concentrations in normal
individuals and in patients with systemic lupus erythe-
matosus (5), and also with susceptibility to invasive
pneumococcal disease. If such polymorphisms, partic-
ularly in the CRP gene itself, can be shown to reliably
correlate with base-line CRP concentrations, and/or
CRP production in the acute-phase response, and also
with clinical outcome, the case for a pathogenetic
and/or host-defense role of CRP in inflammatory dis-
ease will be strengthened.

In most, though not all, diseases (Table 2), the cir-
culating value of CRP reflects ongoing inflamma-
tion and/or tissue damage much more accurately than
do other laboratory parameters of the acute-phase
response, such as plasma viscosity and the erythrocyte
sedimentation rate. Importantly, acute-phase CRP val-
ues show no diurnal variation and are unaffected by
eating. Liver failure impairs CRP production, but no
other intercurrent pathologies and very few drugs
reduce CRP values unless they also affect the underly-
ging pathology providing the acute-phase stimulus. The
CRP concentration is thus a very useful nonspecific
biochemical marker of inflammation, measurement of
which contributes importantly to (a) screening for
organic disease, (b) monitoring of the response to
treatment of inflammation and infection, and (c)
detection of intercurrent infection in immunocom-
promised individuals, and in the few specific diseases
characterized by modest or absent acute-phase respon-
ses (Table 3) (1). It is not known why systemic lupus ery-
thematosus and the other conditions listed with it in
Table 2 fail to elicit major CRP production despite evi-
dent inflammation and tissue damage, nor why the
CRP responses to intercurrent infection are apparent-
ly intact in patients with such conditions.

### Table 1
Changes in concentrations of plasma proteins in the acute-phase response

<table>
<thead>
<tr>
<th>Increased</th>
<th>Decreased</th>
</tr>
</thead>
</table>
| Proteinase inhibitors | α₁-Antitrypsin  
|                       | α₁-Antichymotrypsin  
| Coagulation proteins | Fibrinogen  
|                       | Prothrombin  
|                       | Factor VIII  
|                       | Plasminogen  
| Complement proteins | C1s  
|                       | C2  
|                       | B  
|                       | C3  
|                       | C4  
|                       | C5  
|                       | C1 inhibitor  
| Transport proteins | Haptoglobin  
|                       | Hemopexin  
|                       | Ceruloplasmin  
| Miscellaneous | CRP  
|               | Albumin  
|               | SAA  
|               | Transthyretin  
|               | Fibronectin  
|               | HDL  
|               | α₁-acid glycoprotein  
|               | LDL  
|               | Gc globulin  

### Table 2
CRP responses in disease

<table>
<thead>
<tr>
<th>Major CRP acute-phase response</th>
<th>Bacterial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections</td>
<td>Systemic/Severe fungal, mycobacterial, viral</td>
</tr>
<tr>
<td>Allergic complications of infection</td>
<td>Rheumatic fever</td>
</tr>
</tbody>
</table>
| Inflammatory disease | Erythema nodosum  
|                   | Rheumatoid arthritis  
|                   | Juvenile chronic arthritis  
|                   | Ankylosing spondylitis  
|                   | Psoriatic arthritis  
|                   | Systemic vasculitis  
|                   | Polymyalgia rheumatica  
|                   | Reiter disease  
|                   | Crohn disease  
|                   | Familial Mediterranean fever  
| Necrosis | Myocardial infarction  
| Trauma | Tumor embolization  
| Malignancy | Acute pancreatitis |

<table>
<thead>
<tr>
<th>Modest or absent CRP acute-phase response</th>
<th>Systemic lupus erythematosus</th>
</tr>
</thead>
</table>
|                                          | Scleroderma  
|                                          | Dermatomyositis  
|                                          | Ulcerative colitis  
|                                          | Leukemia  
|                                          | Graft-versus-host disease  

### Structure and phylogeny of CRP
CRP belongs to the pentraxin family of calcium-
dependent ligand-binding plasma proteins, the other
member of which in humans is serum amyloid P com-
ponent (SAP). The human CRP molecule (M, 115,135)
is composed of five identical nonglycosylated polypep-
tide subunits (Mr 23,027), each containing 206 amino
The protomers are noncovalently associated in an annular configuration with cyclic pentameric symmetry (6) (Figure 1). Each protomer has the characteristic "lectin fold," composed of a two-layered \( \beta \) sheet with flattened jellyroll topology. The ligand-binding site, composed of loops with two calcium ions bound 4 Å apart by protein side-chains, is located on the concave face. The other face carries a single \( \alpha \) helix (Figure 1). The pentraxin family, named for its electron micrographic appearance from the Greek \textit{penta} (five) \textit{ragos} (berries), is highly conserved in evolution, with homologous proteins throughout the vertebrates and even in the phylogenetically distant arachnid, \textit{Limulus polyphemus}, the horseshoe crab. SAP, named for its universal presence in amyloid deposits, is a constitutive, non-acute-phase plasma glycoprotein in humans and all other species studied, except the mouse, in which it is the major acute-phase protein. In contrast, mouse CRP is a trace protein whose concentration increases only modestly, to a maximum of about 2 mg/l, during the acute-phase response. No mouse CRP knockout, to our knowledge, has yet been made, and in vivo work on CRP function has largely been confined to passive administration of exogenous, heterologous CRP or to mice transgenic for rabbit or human CRP. These artifactual heterologous systems may not provide physiologically relevant information. Despite the evolutionary conservation of sequence, subunit organization, and protein fold, there are considerable variations between CRPs of different species with respect to fine ligand-binding specificity, presence and nature of glycosylation, protomer assembly, capacity to precipitate and aggregate ligands, base-line circulating concentrations, behavior as acute-phase proteins, and capacity to activate autologous complement (7–9). Indeed, only human CRP has been rigorously shown to activate complement in isologous serum. These differences command extreme caution in extrapolating from animal models to humans.

<table>
<thead>
<tr>
<th>Table 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine clinical uses of CRP measurement</td>
</tr>
</tbody>
</table>

**Screening test for organic disease**

**Assessment of disease activity in inflammatory conditions**
- Juvenile chronic (rheumatoid) arthritis
- Rheumatoid arthritis
- Ankylosing spondylitis
- Reiter disease
- Psoriatic arthropathy
- Vasculitides: Behçet syndrome, Wegener granulomatosis, Polyarteritis nodosa, Polymyalgia rheumatica
- Crohn disease
- Rheumatic fever
- Familial fevers including familial Mediterranean fever
- Acute pancreatitis

**Diagnosis and management of infection**
- Bacterial endocarditis
- Neonatal septicemia and meningitis
- Intercurrent infection in systemic lupus erythematosus
- Intercurrent infection in leukemia and its treatment
- Postoperative complications including infection and thromboembolism

**Differential diagnosis/classification of inflammatory disease**
- Systemic lupus erythematosus vs. rheumatoid arthritis
- Crohn disease vs. ulcerative colitis

**Figure 1**

Molecular structure and morphology of human CRP. (a) Negatively stained electron micrograph showing the typical pentameric disc-like structure face-on and side-on (arrows). (b) Ribbon diagram of the crystal structure, showing the lectin fold and the two calcium atoms (spheres) in the ligand-binding site of each protomer (6). (c) Space-filling model of the CRP molecule, showing a single phosphocholine molecule located in the ligand-binding site of each protomer (6).
plant products. When aggregated or bound to macromolecular ligands, human CRP is recognized by C1q and potentlly activates the classical complement pathway, engaging C3, the main adhesion molecule of the complement system, and the terminal membrane attack complex, C5–C9 (14, 15). Bound CRP may also provide secondary binding sites for factor H and thereby regulate alternative-pathway amplification and C5 convertases.

The secondary effects of CRP that follow ligand binding resemble some of the key properties of antibodies, suggesting that under various circumstances CRP may contribute to host defense against infection, function as a proinflammatory mediator, and participate in physiological and pathophysiological handling of autologous constituents. Evidence of CRP functioning in these various roles is available from experimental animal models, but there is no rigorous information from physiological isologous systems. The absence of any known deficiency or protein polymorphism of human CRP, and the phylogenetic conservation of CRP structure and its ligand-binding specificity for phosphocholine and related substances, suggest that this protein must have had survival value. Microbial infection is a major driving force of change during evolution, and CRP has many features compatible with a role in innate immunity. In addition, the impaired CRP response in active systemic lupus (1) and the marked spontaneous antinuclear autoimmunity of SAP knockout mice (16) are compatible with the possibility that pentraxins function to prevent autoimmunity.

Phosphocholine is a component of many prokaryotes and is almost universally present in eukaryotes (17), and a substantial proportion of germline-encoded, highly conserved natural antibodies resemble CRP in specifically recognizing phosphocholine. The capacity to bind these residues may thus be important for both host defense and handling of autologous constituents (1) including necrotic (18) and apoptotic cells (13, 19). Activation of complement by human CRP may then opsonize and enhance phagocytosis of these various ligands but could also mediate proinflammatory pathophysiological effects (1). Intriguingly, the spectrum of autologous ligands recognized by CRP overlaps that of anti-phospholipid autoantibodies, which may be important for both stable and unstable angina (23, 24), first drew attention to the predictive significance of such measurements for future coronary events. Analysis of CRP values in stored sera from large epidemiological studies rapidly followed, and the subsequent availability of routine high-sensitivity assays for CRP has enabled a flood of studies demonstrating a predictive relationship between increased CRP production and future atherothrombotic events, including coronary events, stroke, and progression of peripheral arterial disease (25–30). Meta-analysis of all published studies up to the year 2000, comprising a total of 1,953 coronary events, showed a relative risk of 2.0 for a future coronary event in subjects with a single initial base-line CRP value in the upper third compared with those in the lower third of the distribution in the general population (29) (see “CRP and atherothrombotic events”). There have been further studies comprising 2,648 coronary events up to the year 2002, and the meta-analysis of these, together with the Reykjavik Icelandic Heart Study of about 19,000 individuals including 2,459 coronary-event patients.

CRP and cardiovascular disease

Earlier work suggested a prognostic association between increased CRP production and outcome after acute myocardial infarction (20) and in acute coronary syndromes (21). However, our original study with high sensitivity measurements of CRP in patients with severe unstable angina (22), and the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study of outpatients with both stable and unstable angina (23, 24), first drew attention to the predictive significance of such measurements for future coronary events. Analysis of CRP values in stored sera from large epidemiological studies rapidly followed, and the subsequent availability of routine high-sensitivity assays for CRP has enabled a flood of studies demonstrating a predictive relationship between increased CRP production and future atherothrombotic events, including coronary events, stroke, and progression of peripheral arterial disease (25–30). Meta-analysis of all published studies up to the year 2000, comprising a total of 1,953 coronary events, showed a relative risk of 2.0 for a future coronary event in subjects with a single initial base-line CRP value in the upper third compared with those in the lower third of the distribution in the general population (29) (see “CRP and atherothrombotic events”). There have been further studies comprising 2,648 coronary events up to the year 2002, and the meta-analysis of these, together with the Reykjavik Icelandic Heart Study of about 19,000 individuals including 2,459 coronary-event patients.

CRP and atherothrombotic events

Raised base-line CRP values predict coronary events, stroke, and progression of peripheral disease
Relative risk of coronary event is 2.0 for single base-line CRP concentration >2.4 mg/l versus <1 mg/l
What is driving this increased CRP production?
- Inflammation in atherosclerotic plaques?
- Total atherosclerotic burden?
- Inflammation elsewhere in the body?
- Metabolic status rather than inflammation?
- Individual higher CRP responsiveness to prevalent endogenous or environmental acute-phase stimuli?

CRP is not uniquely associated with cardiovascular disease; other systemic markers of inflammation show similar associations, though less marked ones than that of CRP.
CRP may therefore be a therapeutic target

Possible specific associations of CRP with cardiovascular disease

| CRP binds selectively to LDL, especially “damaged” LDL |
| CRP is deposited in most atherosclerotic plaques |
| Aggregated and/or ligand-complexed CRP activates complement and can be proinflammatory |
| CRP is co-deposited with activated complement in all acute myocardial infarction lesions |
| Human CRP and complement increase final myocardial infarction size in experimental models |

who underwent follow-up for almost 20 years, is currently in preparation and will provide the most robust estimate to date of the relative risk predicted by CRP.

The recent emphasis in cardiovascular medicine on “high-sensitivity” or “highly sensitive” CRP, abbreviated as so-called hs-CRP, seems to have created a false impression in some quarters that this is somehow a different analyte from “conventional” CRP. This is incorrect. The “high sensitivity” refers simply to the lower detection limit of the assay procedures being used. The actual CRP analyte, the plasma protein that is being measured, is the same regardless of the assay range. Very sensitive CRP assays have been reported from research laboratories for 30 years (1). The new development is the introduction of commercial and automated routine CRP immunoassay systems with greater sensitivity than before.

Circulating CRP values correlate closely with other markers of inflammation, some of which show similar, albeit generally less significant, predictive associations with coronary events (31, 32). The attention focused on CRP reflects in part the fact that it is an exceptionally stable analyte in serum or plasma and that immunoassays for it are robust, well standardized, reproducible, and readily available. Furthermore, the intrinsic biological properties of CRP as an acute-phase reactant are, as explained above, especially favorable for its use as a sensitive quantitative systemic readout of the acute-phase response. In contrast, none of the other systemic markers of inflammation, whether upstream cytokine mediators, other sensitive acute-phase proteins such as SAA, negative acute-phase proteins such as albumin, or cruder multifactorial measures such as erythrocyte sedimentation rate or polymorph count, has such robust and desirable characteristics. The inherent properties of CRP and its behavior may sufficiently explain why it provides closer associations and better predictions than other markers of inflammation. However, CRP may also have specific associations with cardiovascular disease, as discussed below.

Atherosclerosis and inflammation

The mechanisms responsible for the low-grade upregulation of CRP production that predicts coronary events in general populations (27–29) are unknown (see “CRP and atherothrombotic events”). The causes of the often more substantial CRP values associated with poor prognosis in severe unstable angina (22) or after angioplasty are also obscure. Atherosclerosis, and the evolution of plaque instability underlying atherothrombotic events, are inflammatory processes. It has thus been widely assumed, without direct supporting evidence, that the relevant acute-phase stimuli arise from inflammation within atheromatous lesions themselves and reflect their extent and/or severity. This is certainly possible, although there are conflicting observations regarding the association between CRP values and various indirect measures of atheroma burden. However, chronic systemic, nonvascular inflammation is known to be proatherogenic in general, and acute systemic inflammatory episodes are strongly associated with atherothrombotic events. The increased production of CRP that predicts atherothrombotic events may therefore reflect inflammation elsewhere in the body, although there is no correlation with serological evidence of the various chronic microbial infections, such as Chlamydia pneumoniae and Helicobacter pylori, that have been putatively linked with coronary heart disease (29). Another possibility is that individuals vary in their sensitivity to the general background of intercurrent low-grade acute-phase stimuli to which everybody is exposed, and that those who are higher “CRP responders,” through genetic and/or acquired mechanisms, are also more susceptible to progression and complications of atherosclerosis, regardless of whether there is a causal relationship.

There is a strong positive association between baseline CRP concentration and BMI (32), and weight loss lowers the CRP value. Raised base-line CRP values are also associated with many features of the insulin resistance or metabolic syndrome (33, 34), up to and including frank diabetes mellitus (35). This may reflect, in part, the fact that adipocytes are the source of a substantial portion of base-line IL-6 production (36) and perhaps also synthesize and secrete some of the base-line CRP itself. More generally, these associations raise the possibility that aspects of the inflammatory-marker profile associated with increased atherothrombotic risk in the population at large may not be triggered by inflammation or tissue damage in the classical sense. Rather, they may reflect a particular metabolic state that happens also to be proatherogenic and/or to predispose to atherothrombotic events. Indeed, CRP production predicts the development of type 2 diabetes independently of traditional risk factors (37). In insulin-resistant obese individuals, elevated CRP values fall in parallel with improvements in insulin resistance.
that are associated with weight loss, but the association between CRP and insulin resistance is independent of body mass (38). Other potentially important physiological rather than pathophysiological influences are suggested by the finding that oral contraceptive use (39) and systemic, but not transdermal, postmenopausal hormone replacement therapy (40, 41) are also associated with significantly raised base-line CRP concentrations without any sign of tissue-damaging inflammation. Similarly, physical exercise (42) and moderate alcohol consumption (43) are both associated with lowering of base-line CRP concentration. In contrast, the positive association of CRP values with other classical cardiovascular disease risk factors, such as periodontal disease and smoking (32), seems more clearly related to local nonarterial inflammation.

HMG CoA-reductase inhibitors, the drugs known as statins, reproducibly reduce CRP values, independently of their effects on lipid profiles (44). It is not known whether this reflects direct effects on hepatocytes, anti-inflammatory effects within atherosclerotic plaques, and/or anti-inflammatory effects elsewhere. However, recent studies suggest that statins reduce the risk of future cardiovascular events to the same extent in patients with raised LDL cholesterol values and in those with normal LDL but with base-line CRP concentrations above the median (45). If these observations are confirmed, measurement of CRP may become an indication for prophylactic antiatherosclerotic therapy in otherwise apparently low-risk individuals and populations.

However, it is critically important to recognize that the CRP response is nonspecific and is triggered by many disorders unrelated to cardiovascular disease (Table 2). In using CRP for assessment of cardiovascular risk, it is therefore essential to clearly establish true base-line CRP values that are not distorted by either trivial or serious intercurrent pathologies. If the initial CRP result is in the low-risk range, less than 1 mg/l, a single measurement is sufficient, but if it is in the higher-risk range, less than about 2.5 mg/l, two or more serial samples taken at intervals of 1 week or more should be retested until a stable base-line value is seen. If the CRP value persistently remains above 10 mg/l, indicating the presence of a significant acute-phase response, a full history and physical examination of the patient is indicated, ideally together with relevant investigations, to determine the cause and alleviate it if possible. Interestingly, chronic inflammatory conditions, such as rheumatoid arthritis and hemodialysis for end-stage renal failure, that are characterized by persistently elevated CRP concentrations in some individuals, are associated with premature cardiovascular disease.

**CRP and pathogenesis of atherosclerosis?**

Binding of CRP to lipids, especially lecithin (phosphatidyl choline), and to plasma lipoproteins has been known for over 60 years, but the first suggestion of a possible relationship to atherosclerosis came when we demonstrated that aggregated, but not native, nonaggregated, CRP selectively bound only LDL and some VLDL from whole serum (10, 46). However, native CRP does bind to oxidized LDL (19) and to partly degraded LDL, as found in atheromatous plaques, and then activates complement (47). Furthermore, CRP is present in most such plaques examined ex vivo (48, 49). This CRP could promote complement activation and thus inflammation in the plaques, and there is experimental evidence supporting a possible role of complement in atherogenesis (see “Possible specific associations of CRP with cardiovascular disease”). Addition of CRP to LDL in cell culture systems has been reported to stimulate formation of foam cells, which are a typical feature of atherosclerotic plaques (50). It is not known whether this reflects opsonization of the LDL particles by CRP or an effect of CRP on the phagocytic cells themselves. It has been claimed that CRP is recognized by a subset of cellular Fcγ receptors and could thereby directly opsonize its ligands and/or engage multiple processes of inflammation. However, robustly controlled studies, using recombinant and highly purified human CRP and avoiding use of whole IgG anti-CRP antibodies, do not confirm such interactions with human cells (51, 52).

CRP has also been reported to stimulate tissue factor production by peripheral blood monocytes in vitro and could thereby have important procoagulant effects (53). Other studies show a variety of effects in cell cultures exposed to CRP, including, for example, increased expression of adhesion molecules, and modulation of NO synthesis. However, these experiments have generally used commercially sourced CRP of incompletely defined provenance and purity, and there have been few robust specificity controls. The findings must be treated with caution until the purity and structural and functional integrity of the CRP have been rigorously established and the specificity of the observed effects confirmed, for example by comparison with appropriate control proteins and by the use of specific CRP absorbents, ligands, antibodies, and inhibitors of binding.

**CRP and myocardial infarction**

Tissue necrosis is a potent acute-phase stimulus, and, following myocardial infarction, there is a major CRP response, the magnitude of which reflects the extent of myocardial necrosis (20). Furthermore, the peak CRP values at around 48 hours after the onset powerfully predict outcome after myocardial infarction (20, 54–56). Importantly, CRP is co-deposited with activated complement within all acute myocardial infarcts (57, 58), and compelling experimental evidence now suggests that the CRP response not only reflects tissue damage in this context but may also contribute significantly to the severity of ischemic myocardial injury (59).

We specifically investigated in vivo the complement-dependent proinflammatory role of human CRP in rats, taking advantage of the fact that rat CRP does
not activate rat complement while human CRP potently activates both rat and human complement (8). When rats that had undergone coronary artery ligation received daily injections of pure human CRP, they became sicker than similarly operated rats that received buffer alone or the closely related pentraxin human SAP, which does not activate complement (59). Injection of human CRP into unoperated rats had no adverse effects. Some of the coronary artery–ligated rats treated with human CRP died, and those that survived to day 5, when all animals were killed, had infarcts 40% larger than those of buffer- or SAP-treated controls (59). This dramatic enhancement of infarct size by human CRP was completely abrogated by in vivo complement depletion of the rats using cobra venom factor, and hence it was absolutely complement dependent (59).

CRP: a target for therapy in human disease?

We have long speculated that CRP may have significant proinflammatory effects, and that, by binding to ligands exposed on cells or other autologous structures as a result of infection, inflammation, ischemia, and other pathologies, and triggering complement activation, it may exacerbate tissue damage, leading to more severe disease (1). The rat myocardial infarction model provided the first direct evidence of these processes in vivo (59), but they are not necessarily confined to cardiovascular disease. The excellent correlation of circulating CRP concentrations with the severity, extent, and progression of many different pathologies, and the prognostic significance of these associations, are consistent with CRP not just being a marker of disease but also contributing to pathogenesis. A definitive way to test this concept will be the use of novel drugs that specifically block CRP binding and its proinflammatory effects in vivo (60). If these compounds are effective, they may find very broad applicability. Such drugs would be a powerful tool for determining whether increased CRP production merely reflects atherosclerosis or does indeed participate in its pathogenesis and complications, and they could also have cardioprotective effects in acute myocardial infarction. Knowledge of the structure and function of CRP — including its three-dimensional structure alone and complexed with ligands (6) — coupled with experience in developing an inhibitor of the related protein SAP (61) establishes an excellent platform for drug design.

Acknowledgments

G.M. Hirschfield is a Medical Research Council Clinical Training Fellow. The work of the Centre for Amyloidosis and Acute Phase Proteins is supported by grants from the Medical Research Council (United Kingdom), the Wellcome Trust, and the Wolfson Foundation, and by National Health Service Research and Development Funds. We thank Beth Jones for expert assistance in preparing the manuscript.


